2. Academic Validation
  3. Ulinastatin modulates NLRP3 inflammasome pathway in PTZ-induced epileptic mice: A potential mechanistic insight

Ulinastatin modulates NLRP3 inflammasome pathway in PTZ-induced epileptic mice: A potential mechanistic insight

  • Heliyon. 2024 Sep 19;10(19):e38050. doi: 10.1016/j.heliyon.2024.e38050.
Huan Wang 1,  Yuzhu Ma 2,  Dongmei Jin 1,  Xinlei Yang 3,  Xiangping Xu 2
Affiliations

Affiliations

  • 1 Department of Neonatology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • 2 Department of Pediatrics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
  • 3 The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
PMID: 39386862 DOI: 10.1016/j.heliyon.2024.e38050
Abstract

Objective: The NLRP3 (NOD-like Receptor family, pyrin domain containing 3) inflammasome-driven immune-inflammatory response has been shown to play a critical role in epilepsy progression across multiple studies. While Ulinastatin (UTI), an immunomodulatory agent known to target the NLRP3 pathway in neurological disorders, its implications in epilepsy have not been extensively studied. This investigation aims to explore UTI's role and underlying mechanisms in epilepsy.

Methods: To assess UTI's effects on epilepsy severity, neuroinflammation, and BBB integrity, a pentylenetetrazole (PTZ)-induced epilepsy model in mice and a co-culture system involving BV2 and HT22 cells stimulated by lipopolysaccharide (LPS) and ATP were employed. Techniques utilized included qPCR, Western blotting, ELISA, immunohistochemistry (IHC) staining, Evans Blue dye extravasation, glutamate assays, the Morris water maze, and Annexin V Apoptosis assays.

Results: In the PTZ model, UTI administration led to a substantial decrease in seizure intensity and susceptibility, inhibited NLRP3 inflammasome activation, reduced neuroinflammatory interactions, lowered hippocampal and systemic inflammatory mediator levels, and improved cognitive performance. Furthermore, UTI upregulated claudin-5 expression, a tight junction protein in the endothelium, and diminished Evans Blue dye leakage, indicating improved BBB integrity. In BV2 and HT22 cell co-culture models, UTI exerted neuroprotective effects by mitigating microglia-mediated neurotoxicity and fostering neuronal recovery.

Conclusions: The findings demonstrate that UTI exerts transformative regulatory effects on the NLRP3 inflammasome in epilepsy models. This intervention effectively suppresses neuroinflammation, lessens seizure severity and susceptibility, and ameliorates epilepsy-related BBB dysfunction and cognitive impairments.

Keywords

Blood-brain barrier; Epilepsy; NLRP3 inflammasome; Neuroinflammation; Ulinastatin.

Figures
Products